Catalyst Biosciences Inc (NASDAQ:CBIO) shares have come off their early morning high of $9.00, bounced off $5.50 level and now trading above $6 handle.

Infinera (NASDAQ: INFN) Up 17%: CEO Predicts Revenue Growth to Continue

Infinera Corp. (NASDAQ:INFN) reported better-than-expected financial results in the fourth quarter of 2017.
At time of writing INFN was up $1.84 to $8.76. That’s just off the morning high of $8.94. Volume is a record 7.02mm.

The company reported net loss on a GAAP basis of $74.0 million or a loss of 50 cents per share against net income of $36.3 million or 25 cents in the year-ago quarter. Infinera’s adjusted loss of 12 cents was narrower than the Zacks Consensus Estimate of a loss of 13 cents.

Total revenues were $195.8 million, up 8.2% year over year and above the Zacks Consensus Estimate of $189.8 million. Segment-wise, product revenues were $160.54 million, up 6.1% year over year. Services revenues increased 18.9% to nearly $35.27 million. Domestic revenues contributed 53% to the total revenues, while the remaining 47% was generated from international markets.

Total operating expenses were $117.79 million, up from $114.90 million in fourth-quarter 2016.

As of Dec 31, 2017, Infinera’s cash from operations was a negative $21.93 million compared with $38.38 million at the end of 2016.

At the end of December 2017, INFN had $116.35 million of cash and cash equivalents compared with $162.64 million at the end of 2016. The company had no debt against debt of $133.59 million at the end of 2016.

The company continues to face stiff competition from peers like Lantronix, Extreme Networks, NETGEAR NTGR and Brocade Communications Systems in the digital optical networking market.

However, Infinera’s strategic business moves which include launches and alliances look impressive. Different network service providers are merging with the company for the deployment of the Infinera Cloud Xpress, regionally and globally, to reach out to customers with higher scalability and reliability. In November 2017, online streaming service provider, Netflix NFLX , deployed the Infinera Cloud Xpress 2 to expand delivery capacity for streaming videos.

Further, Infinera (NASDAQ:INFN)collaborated with CenturyLink CTL to deliver 2.5 terabits per second of capacity to connect research and education community around the world, leveraging the CenturyLink core network.

About Infinera

Infinera Corporation provides optical transport networking equipment, software, and services worldwide. The company’s product portfolio consists of Infinera DTN-X Family of terabit-class transport network platforms, including the XTC Series, XTS Series, and XT Series; and Infinera DTN platform that supports various Ethernet and optical transport network client interfaces for long-haul, subsea, and regional mesh networks. It also provides Infinera XTM Series carrier-grade packet-optical transport platform that enables high-performance metro networks with service-aware, application-specific capabilities; Infinera XTG Series that is a family of passive optical wavelength-division multiplexing products for metro access applications; and Infinera Cloud Xpress Family multiple platforms that are designed to meet the varying needs of cloud service providers, Internet content providers, Internet exchange service providers, enterprises, and other large-scale data center operators

Jaguar Health Inc. (NASDAQ:JAGX)

Seattle Genetics (SGEN) to Acquire Cascadian Therapeutics (CASC) for $10/Share

Seattle Genetics, Inc. (Nasdaq: SGEN) and Cascadian Therapeutics, Inc. (Nasdaq: CASC) today announced the signing of a definitive merger agreement under which Seattle Genetics has agreed to acquire Cascadian Therapeutics. Under the terms of the agreement, Seattle Genetics will pay $10.00 per share in cash, or approximately $614 million. The transaction was unanimously approved by the Boards of Directors of both companies.

Cascadian Therapeutics’ most advanced program is tucatinib, an investigational oral, small molecule tyrosine kinase inhibitor (TKI) that is highly selective for HER2, a growth factor receptor that is overexpressed in multiple cancers, including breast, colorectal, ovarian and gastric. Tucatinib is currently being evaluated in a randomized global pivotal trial called HER2CLIMB for patients with HER2-positive (HER2+) metastatic breast cancer, including patients with or without brain metastases. Tucatinib has been evaluated as a single agent and in combination with both chemotherapy and other HER2-directed agents including Herceptin® (trastuzumab) and Kadcyla® (trastuzumab emtansine). Results from phase 1b trials showed that the combination of tucatinib, capecitabine and trastuzumab was generally well-tolerated and demonstrated clinical activity in patients with and without brain metastases. The data support the ongoing pivotal trial and the potential role of tucatinib in earlier lines of metastatic breast cancer.

“This acquisition would enhance our late-stage clinical pipeline with a potentially best-in-class, orally available and highly selective TKI for patients with HER2-positive metastatic breast cancer,” said Clay Siegall, Ph.D., President and Chief Executive Officer of Seattle Genetics. “Tucatinib would complement our existing pipeline of targeted cancer therapies, provide a third late-stage opportunity for a commercial product in solid tumors and expand our global efforts in breast cancer. It also leverages our broad expertise and resources to advance and expand the tucatinib program for patients. Beyond breast cancer, we believe there may be opportunities for tucatinib in other tumor types, such as HER2-positive metastatic colorectal cancer. Cascadian’s pipeline also includes a preclinical immuno-oncology agent. We look forward to welcoming the team at Cascadian Therapeutics (Nasdaq: CASC) and continuing the momentum of the tucatinib development program.”


CLS Holdings USA (OTCMKTS:CLSH) Receives a Notice of Allowance from the U.S. Patent Office.

Shares of CLS Holdings USA Inc. (OTCMKTS:CLSH) are trading higher in the wake of the company announcing that it has received a notice of allowance from the U.S. patent office for its proprietary extraction and conversion methodology.

The proprietary extraction process differs from others that typically use ethanol, supercritical CO2 or butane. The resulting finished product is cleaner and provides for more Delta 9 THC. The Company intends to deploy its proprietary extraction and conversion technology upon completion of its pending acquisition of Oasis Cannabis. Additionally, the Company will look to license its patented extraction process.

Jeff Binder, Chairman and CEO of CLS, stated, “Extraction is a very important and valuable process as the quality and value of the finished product is largely impacted by the quality of its extraction. We are focused on increasing yields and the quality of yields and feel our process gives us a major leg up relative to others in the industry. We have dedicated considerable amounts of resources to this endeavor and to receive this allowance from the US patent office is a milestone for the company. I am truly appreciative of all the efforts and contributions of our team and wish to personally thank our chief scientist and co-founder, Ray Keller.”

Stock Analysis

A push by the company to strengthen its cannabis production capabilities appears to have strengthened investors’ confidence on its long-term prospects. The stock is currently trading in an uptrend after gaining more than 50% in response to recent positive news.

For the full year, CLS Holdings USA Inc. (OTCMKTS:CLSH) is up by more than 80%. Given the strength of the upward momentum, the stock should be able to register a new 52-week high as it is currently trading in tight $0.64 to $0.69 range. Lower immediate support looks to be the $0.45 mark. CLS Holdings USA Inc. (OTCMKTS:CLSH) should close the year on the high as it continues to affirm plans to double its cannabis growth production capacity.

Recent Oasis Cannabis Acquisition News

Oasis is an exciting acquisition target as it is set to expand CLS Holdings USA Inc. (OTCMKTS:CLSH) footprint in the business of growing, extracting and processing cannabis products for retail. The company comes into the deal with a growing, conversion and extraction facility that produced $150,000 in gross revenue last month.

The acquisition should be of great benefit to CLS Holdings on the fact that Oasis already generates revenues and has permits to operate dispensaries and deliver products to end consumers.
The parent company also stands to use its proprietary extraction methods to increase the yields from Oasis grow and cultivation businesses. CLSH may also scale Oasis retail business by opening franchises throughout Nevada as well as in other states that have approved marijuana sale.

In addition, the company’s cash balance destined to receive a significant boost upon the closing of the definitive acquisition agreement given that Oasis dispensary serves over 300 customers on a daily basis.
“Since we began this process to acquire Oasis Cannabis a couple of months ago, we have witnessed firsthand its growth and traction in visitors and revenue. We are very pleased with the trends at its grow and retail dispensary and are enthusiastic to move forward to an anticipated closing in the first quarter of 2018,” said CEO, Jeff Binder.

Management Appointment

The appointment of, David Lamadrid, as the President and Chief Financial Officer appears to have strengthened investor confidence in CLS Holdings USA Inc. (OTCMKTS:CLSH). He joins the company with vast experience in management and finance required to lead the firm through the next phase of growth.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $CLSH and receive breaking news on other hot stocks by signing up for our free newsletter!

China Advanced Constructn Mtrls Grp Inc. (NASDAQ:CADC) Market Value Almost Triples!

China Advanced Constructn Mtrls Grp Inc. (NASDAQ:CADC) Market Value Almost Triples!

China Advanced Constructn Mtrls Grp Inc. (NASDAQ:CADC)

China Advanced Constructn Mtrls Grp Inc. (NASDAQ:CADC) shares nearly tripled in market value after the holding company reported Q3 financial results that exceeded Wall Street expectations. Revenue for the three months ended September 30, 2017, nearly doubled as net loss dropped by two thirds.

China Advanced Constructn Mtrls Grp Inc. (NASDAQ:CADC) Market Value Almost Triples!

CADC Stock Performance

China Advanced Constructn Mtrls Grp Inc. (NASDAQ:CADC) stock is currently trading at this year’s highs and close to its 52-week high of high of $9.75 a share. The better than expected financial results appear to have strengthened investor confidence in the company, as the stock had been trading in a downtrend.

Over the past one month, the stock has performed along a premium change of 7.5%. For the past three months, the stock is up by more than 13.1%. However, it is down by 6.5% for the past six months.

The stock grabbed analysts’ attention after spiking on unusual volume. More than 19.31 million shares exchanged hands in Thursday’s trading session compared to a 3-month average volume of 0.02 million and a daily average trading volume of 15.5k shares.

China Advanced Constructn Mtrls Grp Inc. (NASDAQ:CADC) conducts its primary business through subsidiaries. The company engages in the production of construction materials for infrastructure, commercial and residential developments.

Government and industry associations have certified the company’s products. It also boasts of a leading position in the large, highly fragmented ready-mix market concrete market.

CADC Q3 Financial Results

For the three months ended September 30, 2017, the construction company reported revenues of $13.8 million, up from revenues of $7.5 million reported in the corresponding period last year. Cost of revenue surged to $12.3 million from $8.41 million. China Advanced Constructn Mtrls Grp Inc. (NASDAQ:CADC) generated a gross profit of $1.4 million compared to $952,412 reported last year.

“Our management believes that we have the ability to capture a greater share of the Beijing market via expanding relationships and networking, signing new contracts, and continually developing market-leading innovative and eco-friendly ready-mix concrete products,” China Advanced Constructn Mtrls Grp Inc. (NASDAQ:CADC) in a statement.

Net loss for the three months ended September came in at $545,590 compared to a net loss of $5.3 million reported last year. China Advanced Construction Materials exited the quarter with cash and cash equivalent of $923,882 compared to $8.2 million as of the same period last year.

China Advanced Constructn Mtrls Grp Inc. (NASDAQ:CADC) has a Return on Assets of -25.40%. Return on Investment currently stands at -20.55 which means its operations costs outweigh returns.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $CADC and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: James Marion is a University of Houston student studying Business with a concentration in Finance. James has interned with several investment professionals and hopes to pursue a career as a professional stock analyst after graduation.